The Growing SERD Market: Key Drivers and Future Projections Through 2036 #None #AstraZeneca #ETCAMAH #SERD

#EliLilly's oral selective oestrogen receptor degrader (#SERD) #imlunestrant (Inluriyo), has received a second #FDA approval, this time in #combination with #CDK4/6 inhibitor #abemaciclib (Verzenio), another Lilly drug.

pharmaphorum.com/news/lily-ge...